KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Return on Sales: 2018-2025

Historic Return on Sales for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to -1.40%.

  • Moderna's Return on Sales fell 95.00% to -1.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.40%, marking a year-over-year decrease of 95.00%. This contributed to the annual value of -1.10% for FY2024, which is 41.00% down from last year.
  • Moderna's Return on Sales amounted to -1.40% in Q3 2025, which was down 48.02% from -0.94% recorded in Q2 2025.
  • Moderna's 5-year Return on Sales high stood at 0.66% for Q4 2021, and its period low was -1.40% during Q3 2025.
  • Over the past 3 years, Moderna's median Return on Sales value was -0.94% (recorded in 2025), while the average stood at -0.72%.
  • Its Return on Sales has fluctuated over the past 5 years, first soared by 990bps in 2021, then tumbled by 148bps in 2024.
  • Over the past 5 years, Moderna's Return on Sales (Quarterly) stood at 0.66% in 2021, then declined by 23bps to 0.43% in 2022, then tumbled by 112bps to -0.69% in 2023, then slumped by 43bps to -1.12% in 2024, then crashed by 95bps to -1.40% in 2025.
  • Its Return on Sales was -1.40% in Q3 2025, compared to -0.94% in Q2 2025 and -1.08% in Q1 2025.